# A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

> **NCT04974749** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 20 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** REPLAGAL

## Key facts

- **NCT ID:** NCT04974749
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-01-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04974749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04974749, "A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04974749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*